Efficacy and cost-effectiveness of darbepoetin alfa once every 4 weeks versus continuous erythropoietin receptor activator once every 4 weeks for anemia correction in patients with chronic kidney disease not on dialysis

• Autores principales: Geo Neul Park (Autor), Kyung Ho Lee (Autor), Ji Eun Moon (Autor), Soo Jeong Choi (Autor), Moo Yong Park (Autor), Jin Kuk Kim (Autor), Byung Chul Yu (Autor)
• Formato: Libro
• Publicado: The Korean Society of Nephrology, 2024-05-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Background For anemia management in patients with chronic kidney disease not on dialysis, darbepoetin alfa (DA), which has a shorter half-life but is more inexpensive than continuous erythropoietin receptor activator (CERA), is preferred in Korea. This study evaluated the efficacy, safety, and cost-...